Glaxo eyes China R&D

GlaxoSmithKine is evaluating the establishment of a stand-alone research and development center in China, devoted entirely to discovering innovative drugs and healthcare solutions, state media reported. The world’s second-largest pharmaceutical giant, which established its first production plant in China 22 years ago, saw double-digit growth in China revenue last year. It has small R&D units in Beijing, Shanghai and Tianjin and spends 17% of its sales on international R&D every year. "For us, it is more than just doing business in China, it is about being part of the healthcare solutions to China," CEO Jean-Pierre Garnier said.